TC 5214 discontinued for Overactive Bladder-Targacept

Targacept has announced top-line results from a Phase IIb clinical trial of TC 5214 as a treatment for Overactive Bladder (OAB). In the trial, the high dose of TC 5214 demonstrated mixed results on the co-primary endpoints by providing a statistically significant reduction in micturition frequency and an improvement that did not reach statistical significance on episodes of urinary incontinence per 24 hours, after 12 weeks of treatment. TC 5214 was considered generally safe and well tolerated.

However, there was a placebo corrected 15.1% rate of constipation and a 5.9% rate of urinary tract infection in the high dose group. Analyses of the full dataset from the trial are ongoing and Targacept plans to publish more detailed results. As a consequence of these results, Targacept is discontinuing further development of TC 5214 in OAB.